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Background: The endpoint of ablation procedures is suggested to be non-inducibility of paroxysmal atrial
ﬁbrillation (PAF). However, the prognosis of induced AF/atrial tachycardia (AT) after pulmonary vein
isolation (PVI) in PAF patients remains unclear.
Methods: A total of 122 PAF patients were divided into the following 3 groups: Group 1, 79 without AF/AT
induced after PVI; Group 2, 21 with AF/AT induced or sustained after PVI, and followed by a high-
dominant frequency (DF) and continuous complex fractionated atrial electrogram (CFAE) site ablation
and, if necessary, linear ablation; and Group 3, 22 with external cardioversion of AF/AT induced or
sustained after PVI. High-DF (DFZ8 Hz) and continuous CFAE (fractionated intervalsr50 ms) sites were
targeted. The ablation endpoint was non-inducibility of PAF.
Results: In Group 2, AF terminated in 2 patients with a high-DF and continuous CFAE site ablation. In
4 patients, AF induced after cardioversion did not terminate with left atrium linear ablation, and required
additional cardioversion. Common atrial ﬂutter in 2 patients terminated with cavotricuspid isthmus
ablation. An AT terminated with a rooﬂine ablation. Finally, no AF/AT could be induced in any of the
patients in Group 2 after all the procedures. The cumulative freedom from AF/AT recurrence without
antiarrhythmic drugs in Groups 1 and 2 was signiﬁcantly greater than that in Group 3 after 1 procedure
during 12 months of follow-up (90% and 91% vs. 64%, Log-rank test P¼0.001 and P¼0.033, respectively).
Conclusions: Atrial substrate ablation may improve the clinical outcome after ablation in patients after
PVI with residual arrhythmia inducibility.
& 2016 Japanese Heart Rhythm Society. Published by Elsevier B.V. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Catheter ablation is an effective therapy for atrial ﬁbrillation
(AF). Pulmonary vein isolation (PVI) has become an accepted
treatment for AF [1]. Atrial substrate modiﬁcation is considered
necessary in patients with non-paroxysmal AF (NPAF) rather than
paroxysmal AF (PAF) [2,3]. The endpoint of the ablation procedure
has been suggested to be the non-inducibility of PAF. For PAF, an
additional ablation of non-PV AF triggers is considered necessary
in addition to the PVI. However, prior reports showed AF recur-
rence rates of 19–33% in the non-induced group and 36–55% in the
induced group [4–6]. The diagnostic accuracy of AF induction tests
after ablation seems to be low for predicting AF recurrences.
Therefore, the need for further ablation of the induced atrial
arrhythmias after the PVI in PAF patients remains unclear.blished by Elsevier B.V. This is an
: þ81 27 269 1492.
Kumagai),
l.com (D. Kutsuzawa),The efﬁcacy of PVI is sometimes insufﬁcient, and atrial substrate
modiﬁcation of target speciﬁc AF signals indicating the substrate
responsible for AF perpetuation has been proposed [7,8]. Complex
fractionated atrial electrograms (CFAEs), which are electrograms that
show continuous fractionation and very short cycle lengths during
AF, may represent the substrate of AF [7]. In addition, atrial sites that
represent local electrograms with high dominant frequencies (DFs)
may be associated with AF maintenance [8]. A recent study reported
that high-DF sites and continuous CFAE sites as the atrial substrate
following PVI were present even in paroxysmal AF [8]. Accordingly,
the present study aimed to evaluate the need of such an atrial sub-
strate modiﬁcation for the induced atrial arrhythmias after cir-
cumferential PVI to guide the non-inducibility in PAF patients.2. Materials and methods
2.1. Study population
A total of 122 consecutive AF patients with PAF (6479.3 years)
between March 2011 and October 2012 were examined in aopen access article under the CC BY-NC-ND license
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and ethics committee of Gunma Prefectural Cardiovascular Center
on June 15, 2012. All patients provided written informed consent.
The AF duration was 35747 months (range, 2–240). Paroxysmal
AF was deﬁned as AF lasting o7 days [9]. All antiarrhythmic drugs
(AADs) except oral amiodarone administered in 2 patients were
discontinued for at least 5 half-lives, and no patients received any
oral amiodarone therapy before the electrophysiological study.
2.2. Fractionation and frequency analysis
The mapping parameter (CFAE-mean) was deﬁned as an interval-
analysis algorithm that measured the average index of the fractio-
nation. Recordings at each site were 5 s in length [8,10,11]. A con-
tinuous CFAE was deﬁned by an average fractionated interval (FI) of
r50 ms, indicating a high degree of temporal stability of the frac-
tionated electrograms maintaining AF [11,12]. The fast Fourier
transform (FFT) method has been described previously [12]. Signals
were truncated to 3.41 s at sampling rates of 1200 Hz, providing
4096 points for analysis (resolution, 0.29 Hz). The signals were rec-
tiﬁed and processed by a Hanning window function and ﬁltered from
2 to 100 Hz. The point DF was determined as the frequency asso-
ciated with the maximum peak power of the spectrum. Only DF
points with a fast Fourier transform ratio 40.2 were included
[13,14]. The high-DF sites were deﬁned as DFs of Z8 Hz [14].
2.3. Ablation procedure
A NavX system (NavX with CFE software, St. Jude Medical Inc.,
St. Paul, MN, USA) was used for catheter ablation. A 5-french
deﬂectable catheter was inserted into the coronary sinus (CS) via
the right femoral vein. The trans-septal procedure was performed
using ﬂuoroscopic landmarks, and three 8-F SL0 sheaths (St. Jude
Medical Inc.) were advanced into the left atrium (LA). After the
trans-septal procedure, a single bolus of 5000 U of heparin was
administered. A continuous infusion with heparinized saline was
administered to maintain an activated clotting time of 300–350 s.
The three-dimensional biatrial geometry was created on the NavX
system, and sequential contact mapping was performed using a 7-
F decapolar circular catheter (Lasso, Biosense-Webster Inc., Dia-
mond Bar, CA, USA). The points in each region were similar in
number and nearly equally distributed.
The ablation procedure was performed using an approach
consisting of PVI followed by high-DF and continuous CFAE site
ablation and, if necessary, linear ablation. When AF organized into
AT, activation mapping and ablation were performed. The end-
point of the ablation was non-inducibility. The PVI was performed
guided by two 7-F decapolar circular catheters (Lasso, Biosense-
Webster Inc.) positioned at the ipsilateral PV ostia. At the anterior
aspect of the left PVs, an ablation line was created along the ridge
between the left atrial appendage (LAA) and PV ostium. Each
radiofrequency (RF) energy application was delivered for 40 s. A
3.5 mm irrigated tip RF catheter (Saﬁre, St. Jude Medical Inc.) was
used with the temperature limited to 42 °C and power of 30 W
(with a ﬂow rate of 13 mL/min). A maximum power of r25 W
was used while delivering energy to sites near the esophagus.
After the elimination or dissociation of the PV potentials, exit
block was conﬁrmed by pacing from circular catheters placed
within the PVs.
After the PVI, fractionation and frequency analyses were per-
formed for continuous AF or induced AF as mentioned previously
[8,15]. All high-DF sites in the LA, right atrium (RA), and inside the
CS were targeted for ablation, starting with the highest DF points.
Ablation at a DF site was continued for 40–60 s until the local
electrograms were eliminated. A maximum power of r25 W was
used while delivering energy inside the CS. After the high-DF siteablation, the continuous CFAE sites were ablated, starting with the
shortest fractionated interval points. The continuous CFAE site
ablation was performed in the same manner as the high-DF site
ablation.
When AF continued despite a high-DF and continuous CFAE site
ablation, external cardioversion and induction were performed.
For the induced AF, an LA linear ablation consisting of a roof line,
inferior mitral annulus line, or mitral isthmus line was performed.
When AF continued despite a linear ablation, external cardiover-
sion and induction were performed. The procedure was completed
with a cavotricuspid isthmus ablation in all patients who regained
sinus rhythm. Finally, we tried to provoke PV reconnections by
administering 10-mg intravenous injection of intravenous adeno-
sine triphosphate (ATP) administered during an intravenous iso-
proterenol infusion (5 μg/min). Additional RF applications were
performed to eliminate any ATP-reconnections.2.4. Induction protocol
The atrial tachyarrhythmia inducibility was evaluated by a sti-
mulation protocol as mentioned previously [15]. Bursts of 10 beats
were delivered starting at a cycle length (CL) of 250 ms at a pacing
output of 10 mA and 2 ms pulse width. The 10 beat bursts were
repeated with 10 ms decrements for each subsequent burst until
2:1 atrial capture or a minimum CL of 190 ms. The stimulation
protocol consisting of one induction attempt was performed from
the LA using bipolar electrodes in the distal CS without an iso-
proterenol injection. Induced AF/AT was deﬁned as that sustained
for at least 2 min [16].2.5. Post-procedure care and follow-up
A surface electrocardiogram (ECG) and 24-h Holter monitoring
were obtained 1 day after the procedure and repeated 1, 3, 6, 8, 10,
and 12 months thereafter by the referring cardiologist in our
hospital as mentioned previously [15]. Antiarrhythmic medica-
tions were continued for at least 3 months to prevent any early
recurrences of AF unless AF continued. When the patients had any
clinical symptomatic palpitations after the AF ablation, examina-
tions including an ECG, 24-h Holter monitoring, and assessment of
the current condition were also performed on an outpatient basis.
AF recurrence was deﬁned as sustained AF lasting more than 30 s
and conﬁrmed by ECGs 3 months after the ablation [16]. A repeat
ablation procedure was performed if AF recurred or there was an
AT lasting more than 30 s. Procedural success was deﬁned as a lack
of AF or AT beyond 3 months post-ablation [9].2.6. Statistical analysis
Continuous data are expressed as means7SDs. Categorical
variables are expressed as numbers and percentages. If the data
showed a normal distribution, one-way analysis of variance was
performed to identify statistically signiﬁcant differences between
the 3 groups. If the data did not have a normal distribution, the
Kruskal–Wallis H-test was used. A Bonferroni post hoc test was
used to compare the different groups. A Kaplan–Meier event-free
survival analysis was conducted to assess the cumulative freedom
from AF recurrence. Time-to-event analyses were performed using
the Log-rank test. A P value of less than 0.05 was considered sta-
tistically signiﬁcant.
Fig. 1. Flowchart of the patients with the subsequent ablation steps. AF¼atrial
ﬁbrillation; AT¼atrial tachycardia; CFAE¼continuous fractionated atrial electro-











Age (years) 6479.3 64710 6578.4 6678.4 0.485
Men 86 (71%) 55 (70%) 17 (81%) 14 (64%) 0.449
History of AF
(months)
35747 33745 50767 29727 0.302
CHA2DS2-VASc
score
1.771.3 1.771.3 1.771.3 1.671.1 0.969
0 or 1 57 37 10 10 0.990
2 or more 65 42 11 12 0.990
Hypertension 67 (55%) 46 (58%) 11(52%) 10 (45%) 0.555
LA diameter
(mm)
3976.8 3977.4 3976.2 3874.6 0.854
LVEF (%) 6778.5 6879.0 6377.1n 6776.6 0.047
BNP (pg/mL) 74778 77775 917110 44734 0.108
Number of failed
AADs
1.170.5 1.170.4 1.170.4 1.270.9 0.365
Data given as n, n (%), or mean7SD. AADs¼antiarrhythmic drugs; AF¼atrial
ﬁbrillation; BNP¼B-type natriuretic peptide; LA¼ left atrium; LVEF¼ left ven-
tricular ejection fraction.
n Po0.05 vs. Group 1.
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3.1. Patient characteristics
A total of 122 consecutive PAF patents were enrolled. At the
beginning of the procedure, 19 (16%) of the patients were in AF.
While AF/AT could not be induced in 79 (65%) of the patients after
the PVI (Group1), AT/AT could be induced in 39 (32%), and AF
continued in 4 (3%). The patients, except for those in Group 1, were
retrospectively divided into 2 groups as follows: Group 2, 21 with
AF/AT induced or sustained after the PVI, and followed by a high-
DF and continuous CFAE site ablation and, if necessary, linear
ablation; and Group 3, 22 with external cardioversion for the AF/
AT induced or sustained after the PVI (Fig. 1). The patient char-
acteristics are summarized in Table 1. There were no signiﬁcant
differences in the patient characteristics except for the left ven-
tricular ejection fraction. However, the left ventricular ejection
fraction in all patients was within the normal range. None except
for 4 patients (2 with hypertrophic cardiomyopathy and 2 with a
previous myocardial infarction) had structural heart disease.3.2. AF substrate mapping analysis after the PVI
High-DF sites were mainly observed on the posterior wall
(10.6 Hz) and septum (10.7 Hz) of the LA in Group 2 after the PVI.
High-DF sites after the PVI were observed at an average of
5.073.3 sites (3.372.3 in the LA and 1.871.6 in the RA) per
patient. Continuous CFAE sites after the PVI were observed at an
average of 1.272.4 sites (0.972.3 in the LA and 0.270.4 in the
RA) per patient.3.3. Short-term outcome of all procedures
The procedural parameters and follow-up data are summarized
in Table 2. Fig. 1 shows a ﬂowchart of the patients with the sub-
sequent ablation steps. In Group 2, the AF terminated in 2 patients
(a DF at an anterior site and CFAE at a posterior site, respectively)
by ablation at high-DF and continuous CFAE sites (Fig. 2). In
2 patients, common atrial ﬂutter was terminated by cavotricuspid
isthmus ablation. A case of AT was terminated by rooﬂine ablation.
Cardioversion was performed for continuous AF in 16 of 21
patients. In 4 patients, AF induced after cardioversion for con-
tinuous AF did not terminate after an LA linear ablation consisting
of a roof line, inferior mitral annulus line, or mitral isthmus line,
and required cardioversion once more. Finally, no AF or other atrial
arrhythmias could be induced in any of the patients in Group
2 after all the procedures. In Group 3, AF in 20 patients and AT in
1 patient could be induced, and AF continued in 1 patient after the
PVI. Cardioversion was performed for all ATs induced or sustained
after the PVI.
3.4. Long-term outcome of all procedures
The freedom from AF/AT recurrence without antiarrhythmic
drugs was 85% in the PAF patients after 1 procedure over a mean
follow-up of 12 months (Group 1: 90% and Group 2 and 3: 77%).
The recurrence in 1 patient after 3 months was in the form of AT.
The cumulative freedom from AF/AT recurrence without antiar-
rhythmic drugs in Group 1 and Group 2 was signiﬁcantly greater
than that in Group 3 after 1 procedure during 12-months of
follow-up (90% and 91% vs. 64%, Log-rank test P¼0.001 and
P¼0.033, respectively) (Fig. 3). There were no cases of cerebral
infarction, cardiac perforation, tamponade, PV stenosis, or atrial-
esophageal ﬁstula.4. Discussion
The major ﬁndings of this study were as follows: (1) the atrial
substrate modiﬁcation for the patients with induced ATs after the
PVI was effective for AF/AT freedom during 12 months of follow-
up and (2) a high-DF and continuous CFAE ablation and linear
ablation following the PVI could lower the AF inducibility. This
guide of the non-inducibility after the PVI may be useful for
Table 2
Procedural parameters and follow-up data.
All (N¼122) Group 1 (n¼79) Group 2 (n¼21) Group 3 (n¼22) P value
Procedural data
Total procedure duration (min) 182750 184748 217751n 139717nn,† 0.001
Ablation time for PVI (min) 42711 44711 3877n 3478nn 0.001
Ablation time for DF ablation (min) – – 7.6 7 4.2 – –
Ablation time for CFAE ablation (min) – – 4.972.8 – –
AF at the beginning of the procedure 19 (16%) 10 (13%) 6 (29%) 3 (14%) 0.198
AF maintenance after PVI 5 (4%) 0 4 (19%)nn 1 (5%)† 0.001
AF inducibility 34 (28%) 0 14 (67%)nn 20 (95%)nn 0.001
ATs inducibility 4 (3%) 0 3 (14%)nn 1 (5%) 0.004
Clinical outcome
AF/AT recurrence after 3 months 18 (15%) 8 (10%) 2 (10%) 8 (36%)nn,† 0.006
2 procedures 3 (3%) 2 (3%) 1 (5%) 0 (0%) 0.604
AADs usage 16 (13%) 7 (6%) 1 (5%) 8 (36%)n,nn 0.001
AT recurrence 1 (1%) 0 0 1 (5%) –
Data given as n, n (%), or mean7SD. AADs¼antiarrhythmic drugs; AF¼atrial ﬁbrillation;
AT¼atrial tachycardia; CFAE¼continuous fractionated atrial electrogram; DF¼dominant frequency; PVI¼pulmonary vein isolation.
n Po0.05 vs. Group 1.
nn Po0.01 vs. Group 1.
† Po0.01 vs. Group 2.
Fig. 2. Ablation of high-DF sites for induced AF after circumferential PVI in a PAF patient. (A) For induced AF after the circumferential PVI (red tag), all high-DF sites (orange
tag) in the LA were targeted for ablation starting with the highest DF points. (B) By ablation at a high-DF site (8.3 Hz) at an anterior site (pink tag), the AF terminated. (C) The
high-DF site was determined as the frequency associated with the maximum peak power of the spectrum. Non-CFAEs in the CFAE mean maps were deﬁned as those with a
fractionated interval of 4120 ms (purple). ABL¼ablation catheter; AF¼atrial ﬁbrillation; CFAE¼complex fractionated atrial electrograms; CS¼coronary sinus; DF¼do-
minant frequency; L¼ left superior pulmonary vein; LA¼ left atrium; RI¼regularity index; PVI¼pulmonary vein isolation.
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patients with PAF.4.1. Previous studies
The inducibility did not necessarily predict the prognosis [4–6].
These conﬂicting results may depend on the differences in the
modest or aggressive pacing protocols of inducibility: the location
of the pacing sites (RA and/or CS), minimum burst CL from 150 to
200 ms, with or without isoproterenol use, and the deﬁnition ofthe induced atrial arrhythmias (10 s up to 10 min) [4–6]. Further-
more, AF could be induced with an aggressive stimulation protocol
in all patients [17]. The induction of short-term AF may be regar-
ded as a rather non-speciﬁc phenomenon [6]. Therefore, there was
a limitation concerning a more aggressive stimulation protocol
after the AF ablation for the prognosis and guiding further addi-
tional lesion sets in induced atrial arrhythmias because of the
increase in the number of non-speciﬁc AF inductions [4–6].
Our data showed AF/AT freedom rates of 90% in Group 1 and
91% in Group 2 with a possible minimal ablation after the PVI by
Fig. 3. Comparison of the freedom from AF/AT recurrence. The cumulative freedom
from AF/AT recurrence without antiarrhythmic drugs in Group 1 and Group 2 was
signiﬁcantly greater than that in that in Group 3 after 1 procedure during 12-
months of follow-up (90% and 91% vs. 64%, Log-rank test P¼0.001 and P¼0.033,
respectively). AF¼atrial ﬁbrillation; AT¼atrial tachycardia.
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more, both the inducibility and recurrence might be in the form of
AF in almost all cases.4.2. Substrate modiﬁcation in PAF patients
The endpoint of ablation procedures has been suggested to be the
non-inducibility of PAF. In PAF, an additional ablation of non-PV AF
triggers initiating AF is considered necessary in addition to PVI [9].
However, the success rates free of antiarrhythmic drugs and overall
success rates were 74.9% and 83.2%, respectively, in the patients with
paroxysmal AF in the updated worldwide survey [1]. This may
indicate the presence of other atrial substrates that help maintain AF.
A high-DF and continuous CFAE ablation following PVI could also
lower the AF inducibility. Furthermore, the use of PVI with CFAE
ablation for PAF patients did not increase the rate of freedom of ATs,
compared to the use of PVI alone in a previous report by Hayward et
al (79% vs. 74%) [18]. Substrate ablation using CFAE and linear abla-
tion were veriﬁed in the STAR AF II trial as well [19]. However, in the
present study, the number of continuous CFAEs and high-DF sites as
an atrial substrate was lower than that previously described [8],
which may be associated with the AF maintenance. Further, a linear
ablation involving a roof line or mitral isthmus line was needed in
only 4 of 21 (19%) patients in Group 2 because of the achievement of
a lower inducibility by a high-DF and continuous CFAE ablation.
Therefore, by limiting the extent of the RF applications to the atria,
this strategy may help limit occurrences of post-ablation ATs that
follow a more aggressive ablation, which differs from the results of
the STAR AF II trial [19–21].
High-DF and continuous CFAE sites were used as a clinical
surrogate for localized AF sources. We previously reported that a
Z10% CS CL prolongation [15] without any acute AF termination
was observed during the PVI followed by a combined high-DF and
continuous CFAE site ablation and that this strategy could also
render AF non-inducible. This suggested that the atrial substrate
was modiﬁed irrespective of AF termination. The high-DF sites are
reported to be related to the center of a focal-ﬁring rotor or local
reentry circuit and to harbor high-frequency sites, producing afavorable condition for maintenance of AF [22]. Therefore, the
elimination of the harbor sites may render AF non-inducible.
4.3. Clinical implications
A prognosis of induced AF/AT after the PVI in PAF patients
remains unclear. However, the AF/AT freedom without antiar-
rhythmic drugs was lower in the induced Group without a substrate
modiﬁcation. Therefore, a modiﬁcation of atrial substrates with high-
DF sites and continuous CFAE sites among the many CFAEs as a
surrogate for sources of AF maintenance may be needed. Further-
more, relatively fewer potential targets for AF ablation may be ade-
quate to modify atrial substrates. AF/AT could be induced in 35% of
cases after the PVI, which means that a circumferential PVI is a very
effective approach for substrate modiﬁcation, and that atrial struc-
tural and functional impairment emerged owing to atrial ﬁbrosis
resulting from atrial progressive structural remodeling among the
patients with PAF [23]. However, a more aggressive stimulation
protocol after AF ablation may produce an increase in the number of
non-speciﬁc AF inductions [4–6].
4.4. Study limitations
The present study has some limitations. First, it was a single-
center retrospective study with a relatively small population.
Therefore, selection bias of the clinical variables and different
atrial substrates among groups might have existed. Second, the
difference in total procedure time and ablation time for PVI might
have resulted in better durability of PVI and clinical outcome.
However, we performed a ﬁnal veriﬁcation and elimination of
dormant PV conduction at the end of procedure in all patients.
Third, we used a non-aggressive stimulation protocol without an
isoproterenol infusion to decrease the non-speciﬁc atrial arrhyth-
mias and additional lesion sets. Finally, AF recurrence was eval-
uated using surface ECGs and 24-hour Holter monitoring.
Accordingly, asymptomatic AF recurrences may have been over-
looked in the present study. An implantable loop-recorder may
reveal a more accurate AF recurrence rate.5. Conclusions
Non-inducibility of AF/AT after the PVI indicated a greater AF/
AT freedom. A guide of the non-inducibility after the PVI may be
useful for deciding whether additional ablation is needed in
patients with PAF. Atrial substrate ablation may improve the
clinical outcome after ablation in patients after PVI with residual
arrhythmia inducibility.Funding
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